Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pre-menopause Clear all
Terminated Phase 2 Interventional Results available

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

NCT01528345
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dovitinib, Fulvestrant, Dovitinib Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

NCT00161291
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole in combination with Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

NCT01385280
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
therapeutic estradiol, exemestane, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Biological · Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

NCT00232661
View directory record Official record
Conditions
Breast Cancer
Interventions
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
13
States / cities
Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 15, 2026, 3:32 AM EDT
Completed No phase listed Observational Results available

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

NCT05012644
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib + aromatase inhibitor, Aromatase inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder

NCT00626340
View directory record Official record
Conditions
Menopause, Depression
Interventions
MDD diagnosis and Estrogen treatment, MDD diagnosis and Fluoxetine treatment, MDD diagnosis with both Estrogen and Fluoxetine treatment, No depression and estrogen treatment
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

NCT03747042
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Letrozole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

NCT03018366
View directory record Official record
Conditions
Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions
17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 15, 2026, 3:32 AM EDT
Terminated Not applicable Interventional Results available

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

NCT02770768
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 74 Years · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 15, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

NCT00702702
View directory record Official record
Conditions
Uterine Fibroids, Anemia
Interventions
Proellex 25 mg, Proellex 50 mg, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 15, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

Optimal Timing of BR55 CEUS of the Ovaries

NCT04248153
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BR55
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 15, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

NCT06949553
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No study intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 15, 2026, 3:32 AM EDT
Recruiting No phase listed Observational

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT06904365
View directory record Official record
Conditions
Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions
HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 15, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Diet on Vascular Disease in Pre-Menopausal Women

NCT00484861
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Disease, Inflammation, Insulin, Triglycerides
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Midlife Cholesterol Study

NCT00361075
View directory record Official record
Conditions
Menopause, Postmenopause, Premenopause, Cardiovascular Disease
Interventions
transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
47 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2005
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

NCT00277914
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
55
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

NCT00107016
View directory record Official record
Conditions
Breast Neoplasm
Interventions
RAD001, Letrozole 2.5mg, Letrozole 2.5mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 15, 2026, 3:32 AM EDT
Not listed Not applicable Interventional

Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer

NCT03383835
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 Supplementation
Dietary Supplement
Lead sponsor
Lauren Nye
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 15, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

NCT01475513
View directory record Official record
Conditions
Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions
Ortho Cyclen®
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 15, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

NCT05941520
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 15, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

NCT04191382
View directory record Official record
Conditions
Breast Cancer
Interventions
Amcenestrant (SAR439859), Letrozole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • Fort Wayne, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 15, 2026, 3:32 AM EDT
Completed No phase listed Observational

Sex, Aging and Antiretroviral Pharmacokinetics

NCT00666055
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen chosen by treating physician
Drug
Lead sponsor
Kristine Patterson, MD
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 15, 2026, 3:32 AM EDT